Gilead Sciences has commended the leadership of the South African Government and the Global Fund for accelerating early access to its long-acting HIV prevention medication, lenacapavir.
Pfizer has initiated a pivotal Phase 3 study for its 25-valent pediatric pneumococcal vaccine (25vPnC) after Phase 2 data showed a 15-fold increase in immune response against serotype 3.
Topline results from the Phase 3 VALOR study demonstrate that the Lyme disease vaccine candidate (PF-07307405) is safe, well-tolerated, and effective for adults and children.
Despite being influenced by prior vaccinations, the new vaccine produces widely neutralizing antibodies in response.
